In this Exclusive Interview transcript, Dr. Richard Bergenstal discusses the first approval of a hybrid closed-loop system and the future of diabetes treatment, including a possible cure for type 1 diabetes.

In this Exclusive Interview, Dr. Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the technology in the artificial pancreas, the new Abbott Libre CGMS, and the possible diabetes cure.

In this week's Homerun Slides, talking to patients about SGLT-2 as a treatment option.

The glucose transport effector system, GLUT4 vesicle translocation and trafficking: Glucose transport proteins are the key functional units of the glucose transport effector system. Multiple glucose transporter genes have been identified that encode a family of homologous proteins exhibiting different functional properties and marked differences in tissue-specific expression.

In 2006, I had the distinction of doing more education programs for the DIN network than anyone else in the program. Our publisher, Steve Freed, was also part of the more that 400 educators that delivered 1-hour programs to thousands of patients. This was a real change from the all-day …

Let’s start off with what is in the pipeline.

Early initiation of therapy hoped to reduce long-term morbidity, mortality by getting to goal earlier; potentially alter the natural history of the disease.

At diagnosis and shortly thereafter, if their control deteriorates rapidly it could be a sign of asymptomatic pancreatic cancer.

Blood pressure recommendations have been swinging back and forth for a number of decades.

Adults with type 2 diabetes and microvascular complications have an increased risk for severe periodontitis compared with those without microvascular complications.